As I talked about in my opening statement, we are in the process of making available a long-acting antibody for the prevention of COVID in patients who don't mount an immune response to the vaccine, which I think is really important for an untreated population today. The commitment to longer-term development in this space is something that AstraZeneca is doing.
On April 25th, 2022. See this statement in context.